These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 11215878)
41. Risperidone-induced tardive dyskinesia. Hong KS; Cheong SS; Woo JM; Kim E Am J Psychiatry; 1999 Aug; 156(8):1290. PubMed ID: 10450277 [No Abstract] [Full Text] [Related]
42. Increased striatal dopamine transporter levels, as indicated by a DAT scan, induced by ziprasidone in association to improvement of tardive dyskinesia--a case report. Rizos EN; Chatziioannou S; Siafakas N; Douzenis A; Katsantoni E; Mandrapilia A; Bacalis S; Fotiadis C; Lykouras L Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1135-6. PubMed ID: 20460141 [No Abstract] [Full Text] [Related]
43. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. Parellada E; Andrezina R; Milanova V; Glue P; Masiak M; Turner MS; Medori R; Gaebel W J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781 [TBL] [Abstract][Full Text] [Related]
44. Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia. Ezewuzie N; Taylor D J Psychopharmacol; 2006 Jan; 20(1):86-90. PubMed ID: 16174679 [TBL] [Abstract][Full Text] [Related]
45. Tardive dyskinesia during treatment with risperidone. Haberfellner EM Pharmacopsychiatry; 1997 Nov; 30(6):271. PubMed ID: 9442551 [No Abstract] [Full Text] [Related]
46. Risperidone in the treatment of psychosis and concomitant buccolinguomasticatory dyskinesia in the elderly. Koponen HJ Int J Geriatr Psychiatry; 1997 Mar; 12(3):412-3. PubMed ID: 9152730 [No Abstract] [Full Text] [Related]
47. [Long-term relapse prevention with risperidone in 215 schizophrenic patients]. Udina Abelló C; Roca Bennasar M; Octavio Del Valle I Actas Esp Psiquiatr; 2001; 29(4):243-9. PubMed ID: 11470059 [TBL] [Abstract][Full Text] [Related]
48. Signs of striatal dopamine transporter density increase in association with improvement of tardive dyskinesia in a patient with schizophrenia, as demonstrated by a DAT scan. Rizos EN; Chatziioannou S; Douzenis A; Siafakas N; Katsantoni E; Nikolaidou P; Papathanasiou M; Lykouras L Eur Neuropsychopharmacol; 2010 Feb; 20(2):132-6. PubMed ID: 19740630 [TBL] [Abstract][Full Text] [Related]
49. Oral-paliperidone-induced tardive dyskinesia: a case report. Wei HT; Lai YW; Chen MH; Chen YS Gen Hosp Psychiatry; 2012; 34(5):578.e5-6. PubMed ID: 22154659 [TBL] [Abstract][Full Text] [Related]
50. [Improvement of tardive dyskinesia with high doses of propranolol]. Moreira MJ; Karniol IG Rev Paul Med; 1979; 93(3-4):76-8. PubMed ID: 40299 [No Abstract] [Full Text] [Related]
53. Risperidone implicated in the onset of tardive dyskinesia in a young woman. Kumar S; Malone DM Postgrad Med J; 2000 May; 76(895):316-7. PubMed ID: 10775299 [TBL] [Abstract][Full Text] [Related]
54. A case of tardive tremor successfully treated with clozapine. Delecluse F; Elosegi JA; Gérard JM Mov Disord; 1998 Sep; 13(5):846-7. PubMed ID: 9756158 [No Abstract] [Full Text] [Related]
55. Propranolol in the treatment of tardive dyskinesia. Perényi A; Farkas A Biol Psychiatry; 1983 Mar; 18(3):391-4. PubMed ID: 6132627 [No Abstract] [Full Text] [Related]
56. Propranolol, anxiety, and tardive dyskinesia. Bacher NA; Lewis HA J Clin Psychiatry; 1983 May; 44(5):196. PubMed ID: 6133849 [No Abstract] [Full Text] [Related]
57. Antidyskinetic effects of risperidone on animal models of tardive dyskinesia in mice. Carvalho RC; Silva RH; Abílio VC; Barbosa PN; Frussa-Filho R Brain Res Bull; 2003 Apr; 60(1-2):115-24. PubMed ID: 12725899 [TBL] [Abstract][Full Text] [Related]
59. Brief report: risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults. Khan BU J Autism Dev Disord; 1997 Aug; 27(4):479-89. PubMed ID: 9261670 [No Abstract] [Full Text] [Related]
60. Combined treatment of tardive dyskinesia with clonidine and neuroleptics: a follow-up study of three cases for three years. Nishikawa T; Tanaka M; Koga I; Uchida Y Psychopharmacology (Berl); 1983; 80(4):374-5. PubMed ID: 6137858 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]